Advertisement

Indian Journal of Gastroenterology

, Volume 37, Issue 1, pp 72–73 | Cite as

Preliminary experience with sofosbuvir-based treatment regimens for patients dependent on hemodialysis

  • Rajiv Mehta
  • Ketan Desai
  • Mayank Kabrawala
  • Subhash Nandwani
  • Jatin Shah
  • Nisha Desai
  • Viral Parekh
LETTER

Hepatitis C virus (HCV) infection is highly prevalent in patients with end-stage renal disease (ESRD), particularly in hemodialysis-dependent patients (estimated seroprevalence 7.8% to 44%) [1, 2]. Moreover, renal impairment and HCV infection are linked in several important aspects. HCV-infected patients with renal impairment are at increased risk of progression to cirrhosis, hepatocellular carcinoma (HCC), and liver-related mortality [3, 4, 5]. HCV infection also increases the risk of all-cause mortality in patients requiring hemodialysis [6]. Hence, effective antiviral treatment for HCV is of great importance in this cohort. The advent of direct-acting antivirals (DAAs) revolutionized treatment options for HCV-infected patients. In India, the only available DAAs were sofosbuvir (SOF), daclatasvir (DCV), and SOF-ledipasvir (LED) combination. Although SOF is not recommended in patients with severe renal impairment due to predominant renal excretion, increasing evidence of safety and...

References

  1. 1.
    Bhamidimarri KR, Martin P. Finally, safe and effective treatment options for hepatitis C in hemodialysis patients. J Hepatol. 2016;65:7–10.Google Scholar
  2. 2.
    Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology. 2016;150:1590–8.Google Scholar
  3. 3.
    Fabrizi F, Takkouche B, Lunghi G, Dixit V, Messa P, Martin P. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat. 2007;14:697–703.PubMedGoogle Scholar
  4. 4.
    Lee JJ, Lin MY, Chang JS, et al. Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis. PLoS One. 2014;9:e100790.Google Scholar
  5. 5.
    Satapathy SK, Lingisetty CS, Williams S. Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection. Hepatol Int. 2012;6:369–78.Google Scholar
  6. 6.
    Kwon E, Cho JH, Jang HM, et al. Differential effect of viral hepatitis infection on mortality among Korean maintenance dialysis patients: a prospective multicenter cohort study. PLoS One. 2015;10:e0135476.Google Scholar
  7. 7.
    Choudhary NS, Kumar A, Bodh V, et al. Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis. Indian J Gastroenterol. 2017;36:113–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Akhil MS, Kirushnan B, Martin M, Arumugam K, Ganesh Prasad NK, Ravichandran R. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: a retrospective study. Nephrology (Carlton). 2017;  https://doi.org/10.1111/nep.13050.
  9. 9.
    Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36:807–16.Google Scholar
  10. 10.
    Desnoyer A, Pospai D, Le MP, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol. 2016;65:40–7.CrossRefPubMedGoogle Scholar

Copyright information

© Indian Society of Gastroenterology 2018

Authors and Affiliations

  • Rajiv Mehta
    • 1
  • Ketan Desai
    • 2
  • Mayank Kabrawala
    • 1
  • Subhash Nandwani
    • 1
  • Jatin Shah
    • 1
  • Nisha Desai
    • 2
  • Viral Parekh
    • 1
  1. 1.Department of GastroenterologySurat Institute of Digestive SciencesSuratIndia
  2. 2.Department of NephrologySmt RB Shah Mahavir Superspeciality HospitalSuratIndia

Personalised recommendations